Want to see PXMD full AI Analyst Report?
Top Page
PaxMedica, Inc.
(OTC:PXMD)
Select Model
Select Model
Rating:32Underperform
Price Target:―
Action:N/A
Date:01/02/25
PaxMedica's significant financial challenges, including no revenue and negative cash flows, weigh heavily on its stock score. Technical indicators suggest a bearish trend, and valuation metrics are poor with a negative P/E ratio. The lack of guidance or highlights from the earnings call provides limited insight into future prospects, resulting in a low overall score.
Positive Factors
Debt-Free Balance Sheet
Having no debt enhances financial flexibility and reduces risk, allowing PaxMedica to focus resources on R&D and strategic growth initiatives.
Negative Factors
No Revenue Generation
Lack of revenue generation raises concerns about the company's ability to sustain operations and achieve profitability, necessitating strategic changes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Having no debt enhances financial flexibility and reduces risk, allowing PaxMedica to focus resources on R&D and strategic growth initiatives.
Read all positive factors
PaxMedica, Inc. (PXMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.13K
Dividend YieldN/A
Average Volume (3M)37.62K
Price to Earnings (P/E)―
Beta (1Y)57.27
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding126,264,370
10 Day Avg. Volume1,549
30 Day Avg. Volume37,622
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.12
Enterprise Value/Market Cap-73.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PaxMedica, Inc. Business Overview & Revenue Model
Company Description
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorde...
How the Company Makes Money
PaxMedica, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around advancing its clinical pipeline through various stages of research and dev...
PaxMedica, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -17.66M | -16.14M | -16.51M | -7.20M | -5.62M | -599.00K |
| Net Income | -17.66M | -18.29M | -14.80M | -13.04M | -8.49M | -599.00K |
Balance Sheet | ||||||
| Total Assets | 799.61K | 5.68M | 2.20M | 648.87K | 1.12M | 24.95K |
| Cash, Cash Equivalents and Short-Term Investments | 324.49K | 4.71M | 1.90M | 444.09K | 1.12M | 24.95K |
| Total Debt | 0.00 | 0.00 | 173.54K | 0.00 | 611.64K | 0.00 |
| Total Liabilities | 2.61M | 2.30M | 2.10M | 10.76M | 5.75M | 123.25K |
| Stockholders Equity | -1.81M | 3.39M | 108.80K | -10.11M | -4.63M | -98.30K |
Cash Flow | ||||||
| Free Cash Flow | -9.32M | -10.77M | -6.07M | -5.51M | -2.35M | -419.38K |
| Operating Cash Flow | -9.32M | -10.77M | -6.07M | -5.51M | -2.35M | -419.38K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 6.57M | 13.58M | 7.53M | 4.83M | 3.45M | 435.00K |
PaxMedica, Inc. Technical Analysis
0.03
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PXMD, the sentiment is undefined. The current price of 0.03 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for PXMD.
PaxMedica, Inc. Risk Analysis
PaxMedica, Inc. disclosed 53 risk factors in its most recent earnings report. PaxMedica, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PaxMedica, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
PXMD
PaxMedica, Inc.
―
―
―
SCNI
Scinai Immunotherapeutics
2.87
-11.73
-80.34%
ADTX
Aditxt
0.04
-25,628.36
-100.00%
DRMA
Dermata Therapeutics
1.61
-3.74
-69.91%
PBM
Psyence Biomedical
4.32
-14.24
-76.73%
CDT
CDT Equity
1.89
-2,698.11
-99.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.